|
Daehan New Pharm launches two new antibiotic alternative drugs
2008.11.06
|
|---|
|
Daehan New Pharm Co., Ltd. launched VenomMaster, a non-antibiotic treatment for bovine mastitis, in October this year, and DCS682, a non-antibiotic growth promoter for pigs and chickens, in November.
VenomMaster utilizes bee venom, which contains anti-inflammatory, antibacterial, and immune-boosting properties. Developed as a treatment for mastitis, a common infection among dairy cows in Korea, it is the first veterinary pharmaceutical product of its kind to be introduced domestically. The product was commercialized by applying Daehan New Pharm’s advanced pharmaceutical technology to research data accumulated over many years by the Rural Development Administration’s National Institute of Agricultural Sciences. According to reports from major domestic broadcasters (KBS, MBC, YTN, EBS), VenomMaster demonstrated more than 80% treatment efficacy for mastitis cases without the use of antibiotics.
The domestic market for bovine mastitis treatment is estimated to exceed 10 billion won annually, and VenomMaster is expected to secure over 30% of that market in 2009.
DCS682 was jointly developed with the Industry-Academic Cooperation Foundation of Chosun University as part of a project organized by the Agricultural R&D Promotion Center (ARPC) under the Ministry for Food, Agriculture, Forestry and Fisheries. The domestic market for growth-promoting antibiotics is estimated to exceed 20 billion won per year, and DCS682, as a growth-promoting antibiotic alternative, is projected to capture more than 30% of this market in 2009.
Due to growing antimicrobial resistance concerns, the use of antibiotics as growth promoters in compound feed is scheduled to be legally restricted starting in 2009 (according to MIFAFF Notice No. 2007-83). Advanced countries such as those in Europe and the United States have already implemented similar bans, leading to the development of eco-friendly growth promoters and non-antibiotic immune enhancers. Against this backdrop, Daehan New Pharm’s new products are expected to align with the current well-being trend and grow into major “cash cow” items for the company. |


Home